购物车
- 全部删除
- 您的购物车当前为空
Satraplatin (BMS182751) 是一种烷化剂 ,是一种口服的抗肿瘤铂 (IV) 复合物,具有广泛的抗肿瘤效果。
为众多的药物研发团队赋能,
让新药发现更简单!
Satraplatin (BMS182751) 是一种烷化剂 ,是一种口服的抗肿瘤铂 (IV) 复合物,具有广泛的抗肿瘤效果。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 572 | 现货 | |
5 mg | ¥ 1,390 | 现货 | |
10 mg | ¥ 1,970 | 现货 | |
25 mg | ¥ 3,160 | 现货 | |
50 mg | ¥ 4,310 | 现货 | |
100 mg | ¥ 5,830 | 现货 | |
200 mg | ¥ 7,870 | 现货 |
产品描述 | Satraplatin (BMS182751) is an orally available antineoplastic platinum(IV) complex.Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies. |
体外活性 | KB-R 细胞对 satraplatin 没有表现出交叉耐药性。几乎所有转运蛋白的表达状态在 KB-R 细胞中被上调。KB 与 KB-R 细胞之间的 GSH 水平没有差异。流式细胞术分析表明,satraplatin 可以在 KB-R 细胞中引起 G2/M 阶段的阻滞。KB-R 细胞含有富集的侧群细胞[1]。 |
细胞实验 | CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment[1]. |
别名 | BMS182751, JM216, 顺式-二氯-反式-二乙酸-氨-环己胺合铂, BMY45594, 沙铂 |
分子量 | 500.28 |
分子式 | C10H22Cl2N2O4Pt |
CAS No. | 129580-63-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 33 mg/mL (65.96 mM), DMSO inactivates the activity of Satraplatin. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.